Reliance Global Group, through its biotech division LifeSci Global, invested approximately $2 million in Innervate Radiopharmaceuticals, a company developing advanced PET imaging agents for neuroblastoma, a serious pediatric cancer. This investment marks Reliance's entry into the late-stage radiopharmaceutical sector, targeting a $250 million initial market with potential expansion into cardiovascular and neurodegenerative diseases, each possibly exceeding $1 billion. Innervate's lead product, 18F-mFBG, aims to improve cancer imaging with higher resolution and faster scans compared to current standards. The investment aligns with Reliance's strategy to build exposure in high-growth healthcare platforms and could offer significant near-term and long-term value, including potential regulatory incentives like a Priority Review Voucher.
Dycom Industries reported a record first quarter with contract revenues up 56.1% to $1.965 billion and adjusted net income nearly doubling to $134.3 million. The company raised its full-year fiscal 2027 revenue outlook to $7.38-$7.65 billion, driven ...
BrewDog, part of Tilray Brands, is rolling out a major summer campaign across the UK tied to the global football tournament. The campaign features a "Win a Year of Beer" contest with special cans hidden in over 2.8 million packs at major retailers, p...
Autolus Therapeutics, a biopharmaceutical company specializing in next-generation T cell therapies, announced it will present at two upcoming investor conferences: William Blair’s Growth Stock Conference on June 2 and Jefferies Global Healthcare Conf...
Infrastructure Capital Advisors announced the first monthly dividend of $1 per share for its Infrastructure Capital Nasdaq Option Income ETF (QVOL), targeting an annualized distribution rate of 12-15%. The firm also declared monthly dividends for its...
G-III Apparel Group announced a quarterly cash dividend of $0.10 per share, payable on July 8, 2026, to shareholders of record as of June 22, 2026. This dividend reflects the company's ongoing commitment to returning value to its investors. G-III is ...
